Compare PCT & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | BHVN |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | 157 | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2022 |
| Metric | PCT | BHVN |
|---|---|---|
| Price | $5.32 | $8.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $13.00 | ★ $28.85 |
| AVG Volume (30 Days) | ★ 5.4M | 1.9M |
| Earning Date | 05-06-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $366.83 | N/A |
| Revenue Next Year | $201.87 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.12 | $7.48 |
| 52 Week High | $17.37 | $31.18 |
| Indicator | PCT | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 32.34 | 26.55 |
| Support Level | $5.12 | $7.48 |
| Resistance Level | $9.56 | $15.66 |
| Average True Range (ATR) | 0.49 | 0.61 |
| MACD | 0.09 | -0.14 |
| Stochastic Oscillator | 23.08 | 4.37 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.